Back to results

Multicenter, Open-Label, Phase 3 Study to Evaluate the Long-Term Safety and Efficacy in Participants Who Are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab

Objective

To estimate OS

Protocol #

MK-3475-587

Trial Phase:

Phase III

Principal Investigator:

Alesi, Erin

Cancer Type
  • Colon
  • Esophagus
  • Eye and Orbit
  • Larynx
  • Lip
  • Oral Cavity and Pharynx
  • Melanoma
  • Skin
Study Site
  • Stony Point
  • Virginia Commonwealth University

Participants who are at least 18 years of age and treated on a parent study that includes pembrolizumab will be enrolled in this study
Participants from studies that include pembrolizumab (parent studies) established by the Sponsor as KN-587 ready

Get more detailed information at ClinicalTrials.gov

  • Enrollment Status 1
  • Age Group Adult
  • Protocol Type Treatment
  • Research Study Team Carrie Donovan, RN
    Phone: +1 804-628-3836
    Email Study Contact

Click "I'm Interested" to get started. If you have questions, call our study contact.

I'm Interested
Have a question? We're here to help.

Email us or call us with your request.

Send an Email ยป (804) 628-6430
Share: